Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick Naftolin

Showing results (31-40 of 108) with videos related to

Pageof 11
Sort By:
Lancet (London, England)|September 19, 2015
Hormone therapy and ovarian cancerFrederick Naftolin, Jenna Friedenthal, Jennifer Blakemore, et al.
Menopause (New York, N.Y.)|April 12, 2006
Low-dose estrogen therapy for prevention of osteoporosis: working our way back to monotherapySusan Richman, Valentine Edusa, Ahmed Fadiel, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|December 6, 2006
Development of low-dose reproductive hormone therapies in ChinaQinsheng Ge, Qinjie Tian, Hung Tseng, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|December 14, 2007
Menopause: developing a rational treatment planDanielle Vitiello, Frederick Naftolin, Frederick Naftoilin, et al.
Molecular Human Reproduction|May 8, 2002
Hormonal regulation of apoptosis and the Fas and Fas ligand system in human endometrial cellsJoon Song, Thomas Rutherford, Frederick Naftolin, et al.
Fertility and Sterility|August 8, 2008
Angiotensin II induces apoptosis in human mural granulosa-lutein cells, but not in cumulus cellsElisa Acosta, Oscar Peña, Frederick Naftolin, et al.
Journal of Assisted Reproduction and Genetics|November 15, 2025
Overexpression of renin-angiotensin system peptides and receptors (OVRAS) in androgen-induced PCOS mouse ovariesDeborah Rotoli, Frederick Naftolin, Jairo Hernández, et al.
Menopause (New York, N.Y.)|February 23, 2011
The Timing Hypothesis remains a valid explanation of differential cardioprotective effects of menopausal hormone treatmentSeung Do Choi, Emma M Steinberg, Hae Hyeog Lee, et al.
The Journal of Prevention of Alzheimer'S Disease|February 14, 2026
The future of HRT/MHT and Alzheimer's disease risk, onset and progressionEdwin D Lephart, Dawson W Hedges, Frederick Naftolin, et al.
Annals of the New York Academy of Sciences|July 19, 2005
Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidenceS Mitchell Harman, Frederick Naftolin, Eliot A Brinton, et al.
Pageof 11

Showing results (31-40 of 108) with videos related to

Sort By:
Pageof 11
Lancet (London, England)|September 19, 2015
Hormone therapy and ovarian cancerFrederick Naftolin, Jenna Friedenthal, Jennifer Blakemore, et al.
Menopause (New York, N.Y.)|April 12, 2006
Low-dose estrogen therapy for prevention of osteoporosis: working our way back to monotherapySusan Richman, Valentine Edusa, Ahmed Fadiel, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|December 6, 2006
Development of low-dose reproductive hormone therapies in ChinaQinsheng Ge, Qinjie Tian, Hung Tseng, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|December 14, 2007
Menopause: developing a rational treatment planDanielle Vitiello, Frederick Naftolin, Frederick Naftoilin, et al.
Molecular Human Reproduction|May 8, 2002
Hormonal regulation of apoptosis and the Fas and Fas ligand system in human endometrial cellsJoon Song, Thomas Rutherford, Frederick Naftolin, et al.
Fertility and Sterility|August 8, 2008
Angiotensin II induces apoptosis in human mural granulosa-lutein cells, but not in cumulus cellsElisa Acosta, Oscar Peña, Frederick Naftolin, et al.
Journal of Assisted Reproduction and Genetics|November 15, 2025
Overexpression of renin-angiotensin system peptides and receptors (OVRAS) in androgen-induced PCOS mouse ovariesDeborah Rotoli, Frederick Naftolin, Jairo Hernández, et al.
Menopause (New York, N.Y.)|February 23, 2011
The Timing Hypothesis remains a valid explanation of differential cardioprotective effects of menopausal hormone treatmentSeung Do Choi, Emma M Steinberg, Hae Hyeog Lee, et al.
The Journal of Prevention of Alzheimer'S Disease|February 14, 2026
The future of HRT/MHT and Alzheimer's disease risk, onset and progressionEdwin D Lephart, Dawson W Hedges, Frederick Naftolin, et al.
Annals of the New York Academy of Sciences|July 19, 2005
Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidenceS Mitchell Harman, Frederick Naftolin, Eliot A Brinton, et al.
Pageof 11